Pareto Securities and Analysguiden publish research reports; Analysguiden increases price target to SEK 60
Hørsholm, Denmark, November 19, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities and Analysguiden have updated their respective research reports on ExpreS2ion in November, following the publication of Q3 2021 results. Pareto upheld its ‘buy’ rating with a target price of SEK 68 per share, while Analysguiden has increased its fair value estimate from SEK 55 to SEK 60 per share, based on an increased likelihood of approval.Both research reports are available on the Analyst Reports